Scarica l'app Stockscreener
0.0305
15.28%
-0.0055
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Bio Path Holdings Inc Borsa (BPTH) Ultime notizie
Bio-Path (NASDAQ: BPTH) eyes AI crypto treasury despite $2K cash - Stock Titan
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? - Yahoo Finance
US Micro Cap StocksInvest from India - INDmoney
Akari Therapeutics, Plc (AKTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
Bio-Path Holdings, Inc. Revenue Breakdown – OTC:BPTH - TradingView
Akari Therapeutics, Plc (AKTX) stock price, news, quote and history - Yahoo Finance Singapore
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Top News Today/Canada: Producer Prices Continued to Climb in October - Moomoo
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
Antisense Oligonucleotide Pipeline Accelerates as 150+ Pharma - openPR.com
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
Price to sales forward of Bio-Path Holdings, Inc. – OTC:BPTH - TradingView
RNA Therapies Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Price to earnings forward of Bio-Path Holdings, Inc. – OTC:BPTH - TradingView
If You Invested $1,000 in Bio-Path Hldgs Inc (BPTH) - Stock Titan
Marginal Zone Lymphoma Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
ADTX Stock Price and Chart — OTC:ADTX - TradingView
Bio-Path Holdings, Inc. Actuals & Estimates (OTC:BPTH) - TradingView
RNA Interference Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path: Q1 Earnings Snapshot - AOL.com
Bio-Path (OTC: BPTH) unveils crypto treasury plan and $57.9M judgment tie - Stock Titan
[15-12G] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
BIO-PATH HOLDINGS, INC. 1Q 2026: Revenue $0 Net loss $270K, EPS $(0.03) — 10-Q Summary - TradingView
BPTH: Net loss narrowed in Q1 2026 amid operational pause, but liquidity and going concern risks remain acute - TradingView
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash-starved Bio-Path (OTCQB: BPTH) posts Q1 loss and massive dilution - Stock Titan
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer - BioSpace
Bio-Path Holdings Delays Quarterly SEC Filing - TipRanks
Bio-Path (NASDAQ: BPTH) notifies SEC of late Q1 2026 10-Q filing - Stock Titan
Bio-Path Holdings (BPTH) Eps Diluted (Quarterly) - Zacks Investment Research
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Oligonucleotides Clinical Trial Drug Development Pipeline - GlobeNewswire
BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIF - The National Law Review
BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE - EIN News
Stock Market Research, Data and Tools - GuruFocus
BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE SPLIT - EIN News
TTM Technologies, Inc. Files Amendment No. 1 to Form 8-K/A Announcing New Board Appointments – SEC Filing Details - Minichart
Standex International Corporation 2026 Q1 Financial Results and SEC Filing Overview - Minichart
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path - Barchart.com
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Yahoo Finance
Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib - MSN
Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market - openPR.com
MSN Money - MSN
RNA Therapies Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart.com
Layoff Tracker: Replimune lays off over 200 in Massachusetts - BioSpace
XBP Global Holdings, Inc. (NASDAQ:XBP) Has Found A Path To Profitability - Yahoo Finance
5E Advanced Materials, Inc. Files Form 8-K with Nasdaq Listing Details and Emerging Growth Company Status - Minichart
In-Depth Examination of Segments, Industry Trends, and Key - openPR.com
Top News Today/Canada: Goods-Trade Deficit Widens, Surplus With U.S. Narrows - 富途牛牛
Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net
IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
0.17%
0.74%
Capitalizzazione:
|
Volume (24 ore):